Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)
Condition: Relapsed or Refractory Peripheral T-cell Lymphoma Intervention: Drug: Chidamide Sponsor: Great Novel Therapeutics Biotech& Medicals Corporation Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 27, 2023 Category: Research Source Type: clinical trials
Clinical Study of XPO1 Inhibitor Selinexor Combined With COPL in Newly Diagnosed Advanced NK/T-cell Lymphoma
Conditions: nk/T-cell Lymphoma; Newly Diagnosed; Advanced Lymphoma Intervention: Drug: XPO1 inhibitor Sponsor: Chinese PLA General Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 27, 2023 Category: Research Source Type: clinical trials
Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)
Condition: Relapsed or Refractory Peripheral T-cell Lymphoma Intervention: Drug: Chidamide Sponsor: Great Novel Therapeutics Biotech& Medicals Corporation Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 27, 2023 Category: Research Source Type: clinical trials
Clinical Study of XPO1 Inhibitor Selinexor Combined With COPL in Newly Diagnosed Advanced NK/T-cell Lymphoma
Conditions: nk/T-cell Lymphoma; Newly Diagnosed; Advanced Lymphoma Intervention: Drug: XPO1 inhibitor Sponsor: Chinese PLA General Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 27, 2023 Category: Research Source Type: clinical trials
Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)
Condition: Relapsed or Refractory Peripheral T-cell Lymphoma Intervention: Drug: Chidamide Sponsor: Great Novel Therapeutics Biotech& Medicals Corporation Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 27, 2023 Category: Research Source Type: clinical trials
Clinical Study of XPO1 Inhibitor Selinexor Combined With COPL in Newly Diagnosed Advanced NK/T-cell Lymphoma
Conditions: nk/T-cell Lymphoma; Newly Diagnosed; Advanced Lymphoma Intervention: Drug: XPO1 inhibitor Sponsor: Chinese PLA General Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 27, 2023 Category: Research Source Type: clinical trials
Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)
Condition: Relapsed or Refractory Peripheral T-cell Lymphoma Intervention: Drug: Chidamide Sponsor: Great Novel Therapeutics Biotech& Medicals Corporation Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 27, 2023 Category: Research Source Type: clinical trials
Chemotherapy Plus PD-1 Monoclonal Antibody in the Treatment of Refractory or Relapsed Peripheral T-cell Lymphoma.
Conditions: Peripheral T-Cell Lymphoma, Not Otherwise Specified; Angioimmunoblastic T-cell Lymphoma Interventions: Drug: Rituximab; Drug: Gemcitabine; Drug: Dexamethasone; Drug: Cisplatin; Drug: PD-1 monoclonal antibody Sponsors: Ou Bai, MD/PHD; Second Hospital of Jilin University; China-Japan Union Hospital, Jilin University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 20, 2023 Category: Research Source Type: clinical trials